In one paragraphArticle in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Maria F MojicaDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-1380-9824 Scott A BeckaResearch Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
Mitchell EdwardsVenatorx Pharmaceuticals Inc, Malvern, Pennsylvania, USA.
Kyoko UeharaVenatorx Pharmaceuticals Inc, Malvern, Pennsylvania, USA.
Tyuji HoshinoGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Elise T ZeiserResearch Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
Cassandra L ChatwinVenatorx Pharmaceuticals Inc, Malvern, Pennsylvania, USA.
Robert A BonomoDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X Krisztina M Papp-WallaceDepartment of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-9976-7898 Michiyoshi NukagaDepartment of Pharmaceutical Sciences, Josai International University, Togane City, Chiba, Japan.ORCID 0000-0002-3508-3390 Funding
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for BiodefenseR01AI111539 · NIAID · VENATORX PHARMACEUTICALS, INC. · PI BURNS, CHRISTOPHER JOHN, XERRI, LUIGI · 2014 to 2017
$6.1MAdvancement to IND of novel BLI for pairing with cefiximeR44AI109879 · NIAID · VENATORX PHARMACEUTICALS, INC. · PI XERRI, LUIGI · 2017 to 2019
$3.0MBLRD VA I01 BX001974BLRD VA I01 BX002872Japan Society for the Promotion of Science JP20K07484Japan Society for the Promotion of Science JP23H04462National Institute of Allergy and Infectious Diseases 5R44AI109879-04A1National Institute of Allergy and Infectious Diseases R01AI111539NIAID NIH HHS R01 AI111539NIAID NIH HHS R44 AI109879NIH HHS HHSN272201600029CODCDC CDC HHS HHSN272201600029CU.S. Department of Veterans Affairs 1I01BX001974U.S. Department of Veterans Affairs BX002872
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Anti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesBorinic AcidsBurkholderia pseudomalleiAzabicyclo CompoundsCarboxylic AcidsCefepimeCeftazidimeCephalosporinsEscherichia coliMelioidosisMicrobial Sensitivity TestsAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesBorinic AcidsCarboxylic AcidsCefepimeCeftazidimeCephalosporinstaniborbactamBurkholderia pseudomalleicefepimeceftazidimemelioidosisPenIresistancetaniborbactam
Identifiers
PMID40938351
PMCPMC12486822
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390